Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Synsam AB's earnings before interest and taxes (EBIT) for the
three
months ended in Mar. 2026 was kr205 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was kr1,013 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Synsam AB's annualizedROC % for the quarter that ended in Mar. 2026 was 8.03%.
Synsam AB's annualizedROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 49.89%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
Synsam AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 9.26%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Synsam AB EBIT Related Terms
Synsam AB EBIT Historical Data
* Premium members only.
The historical data trend for Synsam AB's EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Synsam AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Synsam AB EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Synsam AB's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Synsam AB's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr1,013 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Synsam AB (OSTO:SYNSAM) has a EBIT of kr1,013 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Synsam AB.
Is Synsam AB's EBIT too high?
Synsam AB's current EBIT is kr1,013 Mil. Overall, Synsam AB has a GF Score™ of 85/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Synsam AB's EBIT compare to ISRG and BDX?
Synsam AB's EBIT of kr1,013 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Synsam AB. Synsam AB's current EBIT is kr1,013 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synsam AB stock overvalued right now?
Based on GuruFocus' analysis, Synsam AB (OSTO:SYNSAM) is currently considered Fairly Valued. The stock's GF Value™ is kr61.30, compared to a current price of kr56.80 — trading 7.3% below its estimated fair value. The current EBIT is kr1,013 Mil. Synsam AB's overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Synsam AB (OSTO:SYNSAM), the current EBIT is kr1,013 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Synsam AB (OSTO:SYNSAM) Overvalued in 2026?
Based on GuruFocus' analysis, Synsam AB stock appears to be undervalued.
The current stock price of kr56.80 is trading 7.3% below its estimated GF Value™ of kr61.30.
GuruFocus considers Synsam AB to be Fairly Valued.
Key valuation signals for OSTO:SYNSAM:
EBIT: kr1,013 Mil
GF Value™: kr61.30 vs. price of kr56.80 (7.3% below fair value)
No single metric tells the full story. See the OSTO:SYNSAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Synsam AB is a lifestyle company in optics and eye health in the Nordic region. The company offers various products and services in physical and digital stores, such as eye examinations, spectacles, sunglasses, sports spectacles, contact lenses, and accessories in optical retail, as well as spectacles subscriptions and related services under the name Synsam Lifestyle. Its stores are operated under the Synsam brand in Sweden, Norway, and Finland, and under the Profil Optik brand in Denmark and Iceland. The company comprises four segments: Sweden, which generates key revenue, Denmark, Norway, and Finland.
85GF Score
Get the complete analysis for OSTO:SYNSAM
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:SYNSAM has been successfully added to your 
